The Pharming Group N.V. is delighted to announce the nomination of Dr. Richard Peters as its new Chairman of the Board of Directors. Dr. Peters brings a wealth of experience and leadership to the company, and the board is confidently looking forward to the positive impact he will have on the Company’s long-term success.
Pharming is delighted to announce that Dr. Peters has been nominated for the role of Non-Executive Director for a four-year term at an upcoming Extraordinary General Meeting of Shareholders (EGM). All necessary information in relation to the EGM, including the notice to convene, will be shared in a separate press release – so keep an eye out!
Dr. Peters is set to join the Board of Directors as an Observer, preparing for his eventual appointment as Non-Executive Director by the EGM. This will offer an invaluable opportunity to gain deeper insight into the inner workings of the Board in anticipation of taking on his new role.
Paul Sekhri, Chairman of the Board, commented:
The Board of Directors is thrilled to announce the nomination of Dr. Richard Peters as the new Chairman. With his impressive track record of success in the development and commercialization of therapies for rare and difficult-to-treat diseases, Dr. Peters will take the reins from the current Chairman upon approval by the general meeting. We are confident he will continue the Board’s mission of advancing global biopharmaceutical innovation and progress.
Richard Peters commented:
I am absolutely delighted to be nominated as the new Chairman of the Board of Directors of Pharming, taking over from Mr. Paul Sekhri! I am highly motivated to team up with my fellow Board of Directors and the Executive Committee to enhance the strong foundations already put in place, and push Pharming to become the go-to rare disease company, dedicating our efforts to those in need of real care and attention. This, of course, is to be accomplished guided by the crystal clear vision and mission of our beloved Pharming.
Dr. Richard Peters has a wealth of experience in the healthcare industry and academia, spanning more than three decades. He is currently Non-Executive Director to two companies: Kineta (NASDAQ:KA) and Aprea Therapeutics (NASDAQ:APRE).
He also serves as a corporate advisor to Aura Biosciences and is the founder and Executive Chairman of TellBio, a private company. With 60 years of age and both a Belgian and US citizenship, Dr. Peters is a respected figure in the healthcare industry.
Dr. Peters is a leader in the field of rare diseases, having most recently served as the Global Head for the Rare Diseases business at Sanofi Genzyme, and CEO of two Nasdaq-listed biotechnology companies: Yumanity Therapeutics and Merrimack Pharmaceuticals.
It wasn’t always that way though – he began his career by holding medical leadership positions at Amgen, Onyx Pharmaceuticals, Genzyme, and Sanofi.
Add to this the founding of X4 Therapeutics (NASDAQ:XFOR) and PIC Therapeutics (private), as well as his faculty role at the Massachusetts General Hospital and his role as an editor for the journals SCIENCE and JAMA, Dr. Peters has established an impressive track record with over 100 published editorial and research articles.
Dr. Peters is an accomplished medical professional with an impressive combination of education and experience. After graduating with an M.D. and a PhD in Pharmacology from the Medical University of South Carolina, he began his medical studies at the Universite Catholique de Louvain in Belgium before immigrating to the US.
For his post-doctoral studies, he earned a Howard Hughes fellowship at Harvard Medical School following his internal medicine training at the world-renowned Massachusetts General Hospital. With both an MD and a PhD, Dr. Peters is well-prepared to take on any challenge or patient care.
About Pharming Group N.V.
Pharming Group N.V. is on a mission to transform the lives of patients across the world who suffer from rare, debilitating and life-threatening diseases. As a global biopharmaceutical company, Pharming specializes in developing and commercializing an innovative portfolio of protein replacement therapies, small molecules, biologics and gene therapies from early- to late-stage development.
With a global presence and employees serving patients across 30 markets, Pharming is headquartered in the Netherlands with a long-term goal to find cures and treatments that relieve suffering for those who need them most.